Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.
Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.
Aura Biosciences (NASDAQ:AURA), a clinical-stage biotech developing precision therapies for solid tumors, will participate in two May 2026 investor conferences.
Management will host fireside chats at the H.C. Wainwright BioConnect Conference and the TD Cowen Oncology Innovation Summit, with live webcasts and 90-day replays on the company’s investor website.
Aura Biosciences (NASDAQ:AURA) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $114.7 million on March 31, 2026, plus $280.8 million in net proceeds from an oversubscribed equity offering, extending cash runway into 2H 2028.
The Phase 3 CoMpass trial in early choroidal melanoma is expected to complete enrollment by mid-2026, with topline data in 2H 2027. Natalie Holles was appointed CEO and President. Net loss rose to $33.7 million, driven by higher R&D and G&A expenses.
Aura Biosciences (Nasdaq: AURA) closed an underwritten public offering on May 5, 2026, selling 46,099,650 common shares (including full exercise of the underwriters' option) and pre-funded warrants to purchase up to 3,800,000 shares.
Securities sold at $6.00 per share and $5.99999 per pre-funded warrant, producing approximately $299.4 million gross proceeds before underwriting discounts, commissions and offering expenses.
Aura Biosciences (Nasdaq: AURA) priced a public offering to sell 39,591,000 shares and pre-funded warrants for up to 3,800,000 shares, at $6.00 and $5.99999 respectively, with gross proceeds expected of $260.3 million. Aura granted underwriters a 30-day option for up to 6,508,650 additional shares. The offering is expected to close on or about May 5, 2026. Aura intends to use approximately $205.1 million of net proceeds, plus existing cash, to advance clinical programs and registration-enabling activities for bel-sar, and to repurchase up to 6,922,870 shares from Matrix at $5.64 per share.
Aura Biosciences (Nasdaq: AURA) launched an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common stock. Aura also intends to give underwriters a 30-day option to buy up to an additional 15% of the offering.
The offering is subject to market conditions and will be made from a Form S-3 shelf registration declared effective April 5, 2024; final terms will appear in a prospectus supplement filed with the SEC.
Aura Biosciences (NASDAQ: AURA) appointed Natalie Holles as CEO, President and board member effective April 30, 2026, replacing founder Elisabet de los Pinos. The company reports its Phase 3 CoMpass trial of belzupacap sarotalocan for early choroidal melanoma is nearing enrollment completion with 86 patients enrolled and >25 more scheduled or identified through May 2026. Aura reiterates enrollment completion by mid-2026 and topline CoMpass data in H2 2027.
Aura Biosciences (NASDAQ: AURA) reported Q4 and full-year 2025 results and program updates on March 30, 2026.
Key points: CoMpass Phase 3 enrollment now expected complete by mid-2026 with topline data in 2H 2027; Phase 1b/2 NMIBC initial 3-month data expected mid-2026; new formulation achieved 12-month stability for non-ocular solid tumors and a patent application was filed; cash and marketable securities totaled $144.2M, funding operations into Q1 2027.
Aura Biosciences (NASDAQ: AURA) said senior management will participate in three investor conferences in March 2026 with live fireside chats and webcasts. Events include TD Cowen on March 4, Leerink Partners on March 10, and Citizens Life Sciences on March 11.
Live webcasts will be available on the company's Investors & Media page and replays will be archived for 90 days after each presentation.
Aura Biosciences (NASDAQ: AURA) will participate in the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025. CEO Elisabet de los Pinos, PhD, will appear in a fireside chat at 10:50 a.m. ET. A live webcast will be available on the company’s Investors & Media Events & Presentations page and a replay will be archived for 90 days following the presentation.
This presentation provides an investor update opportunity with company leadership and a public webcast for remote access.
Aura Biosciences (NASDAQ: AURA) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company now expects to complete enrollment in its global Phase 3 CoMpass trial in 2026 with topline data for the 15-month primary endpoint in Q4 2027. The Phase 1b/2 NMIBC trial remains on track with initial three-month data expected in mid-2026. Phase 1 immune-profiling showed de novo mature tertiary lymphoid structures in 3/5 patients and increases in NK and T-cell densities (NK up to 40x, CD4+ cytolytic up to 7x).
Financials: cash and marketable securities of $161.9M as of Sept 30, 2025, funding operations into the first half of 2027. R&D expense rose to $22.2M (Q3 2025) and net loss was $26.1M for the quarter.